We are live on ! Find out more
CHB

Global X China Biotech Innovation ETF
CHB

Delisted

CHB was delisted on the 16th of February, 2024.

Back to rankings

3 hedge funds and large institutions have $373K invested in Global X China Biotech Innovation ETF in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

34% more capital invested

Capital invested by funds: $278K → $373K (+$95.2K)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$83.3K
2
Citadel Advisors
Citadel Advisors
Florida
+$669

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$9.84K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$197K +$669 +84 +0.3%
Jane Street
2
Jane Street
New York
$176K +$83.3K +10,459 +93%
UBS Group
3
UBS Group
Switzerland
$186 -$9.84K -1,235 -98%

CHB Hedge Fund Activity: Q4 2023 in Review

3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q4 2023, worth a combined $373K — up 34% from $278K a quarter earlier.

Fund positioning in CHB was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, adding an estimated $83.3K. The largest seller was UBS Group, cutting an estimated $9.84K.

  • 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $373K of Global X China Biotech Innovation ETF stock for Q4 2023, up 34% quarter-over-quarter.
  • 0 funds opened new Global X China Biotech Innovation ETF positions in Q4 2023 and 0 closed out.
  • The largest Global X China Biotech Innovation ETF buyer in Q4 2023 was Jane Street, an estimated $83.3K added.
  • The largest Global X China Biotech Innovation ETF seller in Q4 2023 was UBS Group, an estimated $9.84K sold.

Based on aggregated 13F filings for Q4 2023.